Non-small-cell Lung Cancer Clinical Trial
Official title:
Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of pemetrexed and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer (NSCLC).
Status | Completed |
Enrollment | 50 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed, - Unresectable locally advanced (stage IIIB) or metastatic (stage IV) non-squamous NSCLC - At least one and no more than two previous chemotherapy regimens for advanced - or metastatic NSCLC - Measurable disease, defined as at least 1 bidimensionally measurable lesion = 20 X 10 mm. - Age = 18 years. - Performance status (WHO) 0-2. - Life expectancy of at least 12 weeks. - Adequate bone marrow (ANC = 1,500/mm3, PLT = 100,000/mm3, Hgb = 11 g/dL), liver (Bilirubin = 1.5 Upper normal limit, SGOT/SGPT = 2.5 Upper normal limit in the absence of liver metastases or = 5 Upper normal limit in the presence of liver metastases), and renal function (Creatinine = 1,5 Upper normal limit). - Patients must be able to understand the nature of this study and give written informed consent Exclusion Criteria: - Previous therapy with pemetrexed - Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer - Pregnant or lactating women - Any serious, uncontrolled comorbidity on the investigator's judgment. Uncontrolled infection - Any sustained chronic toxicity > grade 2 according to the NCI CTCAE (version 3.0) - Symptomatic neuropathy > grade 2 according to the NCI CTCAE (version 3.0) - Brain metastases, except if radiated and asymptomatic - Radiotherapy within the previous 4 weeks - Previous radiotherapy to the only measurable lesion - Proteinuria = 500 mgr of protein daily - Hemoptysis > 10 cc per event - Clinically significant hematemesis - Centrally located lesion or in contact with major vessels - Pulmonary lesion with cavitation - Documented hemorrhagic diathesis or coagulation disorder - Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF < normal, ventricular arrhythmia, uncontrolled hypertension) - Thrombotic event within the previous 6 months - Concurrent use of aspirin > 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents - Concurrent treatment with other anti-cancer drug - Major surgical procedure within the previous 4 weeks |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Greece | University General Hospital of Alexandroupolis, Dep of Medical Oncology | Alexandroupolis | |
Greece | "Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine | Athens | |
Greece | 401 Military Hospital, Medical Oncology Unit | Athens | |
Greece | Air Forces Military Hospital, Dep of Medical Oncology | Athens | |
Greece | IASO" General Hospital of Athens, 1st Dep of Medical Oncology | Athens | |
Greece | Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases | Athens | |
Greece | Sotiria" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases | Athens | |
Greece | University Hospital of Heraklion | Heraklion | Crete |
Greece | "Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology | Piraeus | |
Greece | Theagenion" Anticancer Hospital of Thessaloniki | Thessaloniki |
Lead Sponsor | Collaborator |
---|---|
Hellenic Oncology Research Group |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival | 1 year | No | |
Secondary | Overall response rate | Objective responses confirmed by CT or MRI (on 3rd and 6th cycle) | No | |
Secondary | Overall Survival | 1 year | No | |
Secondary | Quality of life assessment | Assessment every two cycles | No | |
Secondary | Toxicity profile | Assessment every two cycles | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Not yet recruiting |
NCT02930954 -
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 |